Trade Mark Journal No.2026/038 18 September 2026
WO0000001924299 (5,9,42)
Office of origin: United States of America
Date of International Registration:7 April 2026
Date of designation in the UK:
7 April 2026
International priority date claimed: 7 October 2025
(United States of America)
(99431763)
International priority date claimed: 7 October 2025
(United States of America)
(99431766)
International priority date claimed: 7 October 2025
(United States of America)
(99431768)
- Class 5
- Pharmaceuticals for the treatment of immunoinflammatory diseases and disorders; chemical preparations for pharmaceutical or medical purposes for the treatment of immunoinflammatory diseases and disorders.
- Class 9
- Downloadable software for pharmaceutical product development, for research and data analysis to screen for and identify molecular interactions, compounds and toxicity detection, and for drug discovery and chemical development; downloadable computer software using artificial intelligence (AI) for pharmaceutical product development, for research and data analysis to screen for and identify molecular interactions, compounds and toxicity detection, and for drug discovery and chemical development.
- Class 42
- Pharmaceutical research services; pharmaceutical products development; pharmaceutical drug development services; conducting scientific and pharmaceutical research and data analysis for others to screen for and identify molecular interactions, compounds and toxicity detection; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for drug discovery and chemical development; providing on-line non-downloadable software for pharmaceutical product development, for research and data analysis to screen for and identify molecular interactions, compounds and toxicity detection, and for drug discovery and chemical development; providing on-line non-downloadable software using artificial intelligence (AI) for pharmaceutical product development, for research and data analysis to screen for and identify molecular interactions, compounds and toxicity detection, and for drug discovery and chemical development.
Atomwise Inc.
Representative: John Paul Oleksiuk Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington DE 20004, UNITED STATES OF AMERICA